Beyond GLP-1: The Promise and the Hype Around Peptides - Kilo

Peptides are promoted online as a “magic pill” for almost everything, from faster injury recovery to slowing ageing. Where does real science end and wellness marketing begin?

In an interview with DELFI journalist Agnė Keizikienė, Kristina Žalnieraitė, Chief Nutrition and Science Officer at Kiloverse and Head of Kilo’s Medical Advisory Board, and cardiologist Dr. Robertas Pranevičius, also a member of the board, explore that distinction.

Building on the body’s own signals

Peptides are short chains of amino acids. Many act as biological messengers, helping regulate appetite, blood glucose, metabolism and immune responses.

Scientists can modify these molecules to remain active longer, bind more precisely to specific receptors or reach targets their natural counterparts cannot. The success of GLP-1-based medicines for diabetes and obesity demonstrates what this approach can achieve.

Kristina Zalnieraite
Kristina Žalnieraitė, Head of Kilo’s Medical Advisory Board.

As K. Žalnieraitė explains, the next generation could expand these possibilities. Researchers are exploring peptides that enter cells, deliver therapeutic substances to specific tissues or act on several biological pathways simultaneously. Potential applications extend beyond metabolic diseases to cancer, neurological disorders and antibiotic-resistant infections.

The opportunity lies not only in discovering useful peptides in nature, but in designing molecules with increasingly precise biological functions.

Keeping enthusiasm grounded in evidence

The word “peptide” describes a type of molecule, not proof of safety or effectiveness. Approved peptide medicines and experimental products can have very different levels of scientific evidence behind them, and some widely promoted peptides still lack high-quality clinical research in humans.

Medical Board Member, doctor Robertas Pranevičius.
Dr. Robertas Pranevičius, Member of Kilo’s Medical Advisory Board.

R. Pranevičius stresses the importance of discussing peptide use openly with patients, while acknowledging a key limitation: long-term data are still missing for the experimental products people ask about.

Peptide science deserves attention, but meaningful progress depends on rigorous research, reliable manufacturing and informed conversations between patients and healthcare professionals.

Read the full interview on DELFI (in Lithuanian)

Read more